Sign Up for Free!

Continue Analyzing the page and more.

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Ticker Image

US$0

US$517.0m

-2.0%

46.8%

Overview Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Ratio
Dashboard Funda..tals Deep..lue Prediction Screener Map

Xeris Pharmaceuticals Inc Overview

Industry: Biotechnology

Sector: Healthcare

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company markets Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company markets Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalem Read More

Xeris Pharmaceuticals Inc is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

Xeris Pharmaceuticals Inc

Score

Recent News



Earnings Per Share

Score 3.00/5
Xeris Pharmaceuticals Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc UnitedHealth Group Incorporated IQVIA Holdings Inc
In Biotechnology industry , Vertex Pharmaceuticals Inc , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated are companies with high ratings.

Return on Equity

Score 0.14/5
Xeris Pharmaceuticals Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc UnitedHealth Group Incorporated IQVIA Holdings Inc

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

In Biotechnology industry , Vertex Pharmaceuticals Inc , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated are companies with high ratings.

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

Net Margin

Score 1.81/5
Xeris Pharmaceuticals Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc UnitedHealth Group Incorporated IQVIA Holdings Inc

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

In Biotechnology industry , Vertex Pharmaceuticals Inc , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated are companies with high ratings.

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

Share Buyback

In Biotechnology industry , Vertex Pharmaceuticals Inc , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated are companies with high ratings.

Leverage

Score 1.18/5
Xeris Pharmaceuticals Inc registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc UnitedHealth Group Incorporated IQVIA Holdings Inc have achieved high scores.

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

In Biotechnology industry , Vertex Pharmaceuticals Inc , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated are companies with high ratings.

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

Financial Ratio

Yearly Quarterly

Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios

Ticker Image

Xeris Pharmaceuticals Inc

US$0

US$517.0m

-2.0%

46.8%